Early implementation of an electronic measurement-based care tool in substance use disorder treatment clinics.

J Subst Use Addict Treat

NYU Langone Health, Department of Population Health, 180 Madison Ave., New York, NY 10016, United States.

Published: December 2024

Background: Measurement-based care (MBC), routinely measuring and reviewing treatment progress with a standardized tool, can inform clinical decision making and improve patient outcomes. Despite potential benefits, implementation of MBC in SUD treatment settings has been limited and little is known about its implementation in SUD settings. The goal of this convergent parallel mixed methods study was to understand staff experiences during early implementation of MBC in SUD treatment clinics.

Methods: The Treatment Progress Assessment-8 (TPA8) is an 8-item measure that supports MBC with an electronic system (eTPA8) allowing client completion on electronic devices and providing staff reports. The study introduced the eTPA8 into 13 clinics using external practice facilitation and implementation teams. Quantitative data examining implementation included eTPA8 system data (1672 administrations) and staff surveys (n = 70) using feasibility, acceptability, and appropriateness measures. Semi-structured interviews (n = 34) were conducted with clinic staff. To analyze data, we classified clinics into adopters, non-adopters, and sustainers using eTPA8 system data. One-way ANOVA compared these classifications on the three implementation outcome measures. Rapid qualitative analysis was used for the interviews.

Results: There were significant differences between staff in sustainer (M = 3.90) and non-adopter (M = 3.21) clinics on the feasibility measure (F(2, 68) = [4.28], p = 0.018). SUD program staff found the eTPA8 to be user-friendly, appropriate, and acceptable. There was some variation in perceived feasibility of regular use of the eTPA8, especially given competing demands and time constraints. Staff found the eTPA8 useful to support clinical interactions but varied in embracing new technology and the overall MBC concept. The inner and outer contexts influenced implementation and required attention by clinic champions and implementation teams. External practice facilitators were key to addressing barriers in an ongoing and flexible manner.

Conclusions: Implementing MBC using the eTPA8 showed promise. Staff felt the TPA8 was generally clinically useful, appropriate, and acceptable; yet feasibility was variable. Adoption of MBC faced barriers (e.g., competing demands). Implementation required relatively intensive implementation supports that were dynamic, proactive, and responsive. Findings have implications for guiding development and refinement of responsive, theory-driven implementation strategies to support MBC in SUD treatment settings, with a particular focus on addressing feasibility.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.josat.2024.209605DOI Listing

Publication Analysis

Top Keywords

mbc sud
12
sud treatment
12
implementation
11
early implementation
8
measurement-based care
8
mbc
8
treatment progress
8
implementation mbc
8
treatment settings
8
staff
8

Similar Publications

Background: Substance use disorders (SUDs), encompassing alcohol (AUDs) and drug use disorders (DUDs), are significant global public health concerns. While SUDs are well-documented worldwide, data on their prevalence and impact in Saudi Arabia remain scarce. This study investigates the epidemiology and burden of SUDs in Saudi Arabia using data from the Saudi National Mental Health Survey (SNMHS).

View Article and Find Full Text PDF

Early implementation of an electronic measurement-based care tool in substance use disorder treatment clinics.

J Subst Use Addict Treat

December 2024

NYU Langone Health, Department of Population Health, 180 Madison Ave., New York, NY 10016, United States.

Background: Measurement-based care (MBC), routinely measuring and reviewing treatment progress with a standardized tool, can inform clinical decision making and improve patient outcomes. Despite potential benefits, implementation of MBC in SUD treatment settings has been limited and little is known about its implementation in SUD settings. The goal of this convergent parallel mixed methods study was to understand staff experiences during early implementation of MBC in SUD treatment clinics.

View Article and Find Full Text PDF

The lived experience of renal cachexia: An interpretive phenomenological analysis.

Int J Nurs Stud Adv

December 2024

School of Nursing and Midwifery, Queen's University Belfast, MBC Building, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom.

Article Synopsis
  • - Chronic kidney disease affects around 13% of the global population and is expected to be a major cause of life years lost by 2040, with end-stage kidney disease leading to complications like renal cachexia, which is not well understood and has limited treatment options.
  • - The study aims to understand the experiences of individuals with renal cachexia and their carers through in-depth interviews, adhering to ethical research practices in a UK healthcare setting.
  • - Seven participants (four patients and three carers) were recruited, with the data analyzed to identify six key themes related to their lived experiences, including issues like appetite loss, weight decline, social withdrawal, and emotional struggles.
View Article and Find Full Text PDF

Purpose Of Review: Precision medicine prioritizes characterization of individual patient parameters to optimize care and this review evaluates measurement-based care (MBC) as a strategy for doing so in the treatment of substance use disorders (SUD). Measurement-based care refers to the systematic use of validated assessments to inform diagnosis and treatment planning, with varying frequency of assessments. Despite the seemingly obvious grounds for the use of MBC in treating SUD, systematic implementation to date has been limited.

View Article and Find Full Text PDF

Purpose: The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC), with median progression-free survival (PFS) of 8.11 months, which was similar to that in the olaparib arm of the phase III OlympiAD trial (7.03 months).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!